Clinical Trial Update: Icotinib as Adjuvant Therapy in Treating Non-small-cell Lung Cancer Patients With Positive EGFR Mutation [Phase 2]

View source ↗

Summary

This update describes a Phase 2 trial evaluating icotinib as adjuvant therapy for patients with EGFR-mutant non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• icotinib (icotinib)

Snippet

Sponsor: Betta Pharmaceuticals Co., Ltd. | Conditions: Non-small-cell Lung Cancer | Phase 2 | Status: UNKNOWN